SCLC, EXTENSIVE STAGE
Clinical trials for SCLC, EXTENSIVE STAGE explained in plain language.
Never miss a new study
Get alerted when new SCLC, EXTENSIVE STAGE trials appear
Sign up with your email to follow new studies for SCLC, EXTENSIVE STAGE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to stall aggressive lung cancer
Disease control Recruiting nowThis study tests whether a combination of two drugs (adebrelimab and etoposide) can help keep extensive-stage small cell lung cancer from progressing after initial chemotherapy. About 32 adults aged 18-75 who have not worsened after standard treatment will receive the drug combo …
Matched conditions: SCLC, EXTENSIVE STAGE
Phase: PHASE2 • Sponsor: Tang-Du Hospital • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
Cancer-Killing virus joins forces with chemo to fight tough lung cancer
Disease control Recruiting nowThis study tests a new treatment for advanced small cell lung cancer that has stopped responding to standard platinum chemotherapy. The treatment combines an oncolytic virus (Olvi-Vec) with a platinum-based chemo and etoposide. The goal is to see if this combination is safe and c…
Matched conditions: SCLC, EXTENSIVE STAGE
Phase: PHASE1, PHASE2 • Sponsor: Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New daily pill shows promise for Tough-to-Treat cancers
Disease control Recruiting nowThis study tests a new daily pill, ABP1011T, in people with advanced solid tumors like small cell lung cancer, esophageal cancer, cervical cancer, bladder cancer, and renal cell carcinoma. Participants take one tablet each day on an empty stomach in 21-day cycles. The goal is to …
Matched conditions: SCLC, EXTENSIVE STAGE
Phase: PHASE2 • Sponsor: Shanghai AB PharmaTech Ltd. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New combo therapy aims to fight aggressive lung cancer in japanese patients
Disease control Recruiting nowThis study tests a new drug (HLX10) that helps the immune system fight cancer, combined with standard chemotherapy, in 26 Japanese patients with extensive-stage small cell lung cancer that hasn't been treated before. The main goal is to see how many patients' tumors shrink or dis…
Matched conditions: SCLC, EXTENSIVE STAGE
Phase: PHASE2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
New drug combo aims to keep advanced lung cancer in check
Disease control Recruiting nowThis study tests a combination of two drugs (golidocitinib and a PD-1 inhibitor) as maintenance treatment for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this combo can delay cancer growth or improve survival. About 20 a…
Matched conditions: SCLC, EXTENSIVE STAGE
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated May 11, 2026 20:38 UTC
-
Engineered immune cells take aim at Hard-to-Treat lung cancer
Disease control Recruiting nowThis study tests a new treatment using specially engineered immune cells (CAR-NK cells) that target multiple markers on small cell lung cancer cells. The goal is to see if these cells are safe and can shrink tumors in adults whose cancer has returned or not responded to standard …
Matched conditions: SCLC, EXTENSIVE STAGE
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated May 08, 2026 12:04 UTC
-
New combo therapy aims to extend remission in aggressive lung cancer
Disease control Recruiting nowThis study tests whether adding the drug niraparib to standard immunotherapy can help keep extensive-stage small cell lung cancer from progressing. It is for people whose tumors have a specific marker called SLFN11 and who have not worsened after initial treatment. About 44 parti…
Matched conditions: SCLC, EXTENSIVE STAGE
Phase: PHASE2 • Sponsor: ETOP IBCSG Partners Foundation • Aim: Disease control
Last updated May 07, 2026 18:42 UTC
-
New hope for aggressive lung cancer: targeted radiation plus immunotherapy tested in maintenance phase
Disease control Recruiting nowThis early-phase study tests whether adding a targeted radioactive drug ([225Ac]Ac-DOTATATE) to an immunotherapy (tislelizumab) can help control extensive-stage small cell lung cancer after initial treatment. About 24 adults whose tumors have a specific marker (SSTR) will receive…
Matched conditions: SCLC, EXTENSIVE STAGE
Phase: PHASE1 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated May 07, 2026 18:41 UTC
-
Promising new scan may spot lung cancer more precisely
Diagnosis Recruiting nowThis study tests a new radioactive probe called PFD3 that targets a protein (DLL3) found on small cell lung cancer cells. Using PET/CT scans, doctors hope to see tumors more clearly and assess the cancer's spread. About 30 adults with confirmed small cell lung cancer will receive…
Matched conditions: SCLC, EXTENSIVE STAGE
Phase: PHASE1, PHASE2 • Sponsor: Peking University First Hospital • Aim: Diagnosis
Last updated May 15, 2026 11:53 UTC